# Barbara Eichhorst

Source: https://onco.cc/people/barbara-eichhorst/  
OnCo record `barbara-eichhorst` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CLL13 (GAIA), showing venetoclax-based fixed-duration therapy beats chemoimmunotherapy in fit CLL patients.

## Summary

Barbara Eichhorst was principal investigator of CLL13/GAIA, the trial showing venetoclax plus obinutuzumab, with or without ibrutinib, achieves higher MRD-negativity and longer progression-free survival than FCR or BR in fit patients with untreated CLL, extending fixed-duration therapy to the fit population. She led CLL10 (FCR versus BR) and chairs the ESMO CLL guidelines.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cll; venetoclax; guidelines
- Role: Professor of Medicine and Head of the CLL Outpatient Clinic, University Hospital Cologne; Secretary, German CLL Study Group
- Specialisms: Chronic lymphocytic leukaemia; Time-limited combinations; Chemoimmunotherapy; Guidelines

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Eichhorst%20B%5BAuthor%5D%20chronic%20lymphocytic%20leukemia

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [CD20](https://onco.cc/targets/cd20/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- institutions: [Uniklinik Köln (CIO)](https://onco.cc/institutions/uniklinik-koeln/)
- trials: [CLL13 / GAIA](https://onco.cc/trials/cll13-gaia/)

---
JSON: https://onco.cc/api/v1/entities/barbara-eichhorst.json